BRIEF-Aeterna and Rafa Laboratories sign license agreement for Zoptrex in Israel
Aug 1 (Reuters) - Aeterna Zentaris Inc
* Aeterna Zentaris and Rafa Laboratories sign exclusive license agreement for Zoptrex in Israel
* Company expects to complete phase 3 clinical trial in Q3 of 2016
* Company and Rafa have also entered into a supply agreement
* Entitled to receive a non-refundable upfront payment in consideration for license to Rafa of intellectual property related to Zoptrex
* Company will supply Zoptrex to Rafa for duration of license agreement Source text for Eikon: Further company coverage:
© Thomson Reuters 2017 All rights reserved.